Open AccessConditional Approval of Cancer Drugs in Canada: Accountability and Impact on Public Funding
Author(s) -
Sarah K. Andersen,
Natasha Penner,
Alexandra Chambers,
Maureen Trudeau,
Kelvin Chan,
Matthew C. Cheung
Publication year - 2019
Publication title -
current oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.053
H-Index - 51
eISSN - 1718-7729
pISSN - 1198-0052
DOI - 10.3747/co.26.4397
Subject(s) - medicine , accountability , cancer drugs , drug approval , family medicine , pharmacology , political science , law , drug
We examined how conditional market approval of cancer pharmaceuticals by Health Canada (hc) affects public funding recommendations by the pan-Canadian Oncology Review (pcodr). We were also interested to see how often hc conditions are enforced.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom